Wall Street analysts predict that ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) will report ($0.23) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for ESSA Pharma’s earnings. ESSA Pharma posted earnings of ($0.39) per share in the same quarter last year, which would suggest a positive year over year growth rate of 41%. The firm is scheduled to announce its next quarterly earnings results on Thursday, December 12th.
According to Zacks, analysts expect that ESSA Pharma will report full year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.52) to ($1.11). For the next financial year, analysts forecast that the company will report earnings of ($1.20) per share, with EPS estimates ranging from ($1.49) to ($0.91). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for ESSA Pharma.
Several analysts have recently weighed in on the company. ValuEngine upgraded ESSA Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating on shares of ESSA Pharma in a research report on Friday, May 17th. Finally, Zacks Investment Research upgraded ESSA Pharma from a “sell” rating to a “buy” rating and set a $2.50 target price for the company in a research report on Wednesday, May 22nd.
Shares of NASDAQ:EPIX traded up $0.05 on Friday, hitting $1.51. 6,600 shares of the company’s stock were exchanged, compared to its average volume of 21,551. ESSA Pharma has a 12 month low of $1.41 and a 12 month high of $4.50. The stock has a market capitalization of $13.38 million, a price-to-earnings ratio of -0.59 and a beta of 1.93. The business’s 50 day simple moving average is $2.27 and its two-hundred day simple moving average is $2.79. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.44 and a quick ratio of 2.44.
ESSA Pharma Company Profile
ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
See Also: SEC Filing
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.